Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 1 Study of CX1003 (Kanitinib) in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04093466
Recruitment Status : Recruiting
First Posted : September 18, 2019
Last Update Posted : January 14, 2022
Sponsor:
Collaborators:
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
West China Hospital
Beijing Tongren Hospital
Information provided by (Responsible Party):
Beijing Konruns Pharmaceutical Co., Ltd.

Brief Summary:
CX1003 is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit vascular endothelial growth factor receptor 2 (VEGFR2) and hepatocyte growth factor receptor (HGFR/MET). This study aimed to evaluate the safety, pharmacokinetics, and antitumor activity of CX1003 in patients with refractory advanced or metastatic solid tumors.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumor Drug: CX1003 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 126 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Multicenter, Open-label, Dose Escalation/Expansion Study Evaluating the Safety, Pharmacokinetics and Preliminary Efficacy of CX1003 (Kanitinib) in the Patients With Relapsed Advanced or Metastatic Solid Tumors
Actual Study Start Date : April 27, 2020
Estimated Primary Completion Date : November 2022
Estimated Study Completion Date : November 2022

Arm Intervention/treatment
Experimental: Treatment (CX1003)
Treatment will comprise 2 periods: a 4-day single dose period, followed by a period of daily-dose in continuous 28-day treatment cycle (the 1st cycle) or 21-day treatment cycles (the 2nd cycle and beyond).
Drug: CX1003
Oral dose A 4-day single dose period, followed by a period of daily-dose in continuous 28-day treatment cycle (the 1st cycle) or 21-day treatment cycles (the 2nd cycle and beyond) Dosage range: 25 mg, 50mg, 75mg, 100mg,125mg,150mg,175mg
Other Name: kanitinib




Primary Outcome Measures :
  1. Incidence of dose-limiting toxicities (DLTs) by NCI CTCAE 5.0: Dose Escalation Stage [ Time Frame: First 5 weeks after initial administration of CX1003 ]

    Occurrence of any of the following toxicities was considered DLT if judged by the Investigator to be possibly, probably, or definitely related to the administration of CX1003:

    • Any Grade 3 or higher non-hematologic toxicity (including persisting nausea, vomiting, diarrhea, and electrolyte imbalances despite optimal medical management);
    • Grade 4 neutropenia for >5 consecutive days;
    • Grade 3 or higher febrile neutropenia;
    • Grade 3 or higher neutropenia associated with infection;
    • Grade 4 thrombocytopenia;
    • Grade 3 or higher thrombocytopenia with clinically significant bleeding or that requires a platelet transfusion.

  2. Maximum tolerated dose (MTD): Dose Escalation Stage [ Time Frame: First 5 weeks after initial administration of CX1003 ]
    The maximum tolerated dose (MTD) was defined as the highest dose for a given schedule that was expected to cause DLTs in no more than 33% of patients.


Secondary Outcome Measures :
  1. Pharmacokinetics (PK) profile: Cmax [ Time Frame: First 5 weeks after initial administration of CX1003 ]
    Parameters: Peak Plasma Concentration (Cmax)

  2. Pharmacokinetics (PK) profile: Tmax [ Time Frame: First 5 weeks after initial administration of CX1003 ]
    Parameters: Time to reach the maximum plasma concentration (Tmax)

  3. Pharmacokinetics (PK) profile: T1/2 [ Time Frame: First 5 weeks after initial administration of CX1003 ]
    Parameters: Terminal half-life (T1/2)

  4. Pharmacokinetics (PK) profile: AUC [ Time Frame: First 5 weeks after initial administration of CX1003 ]
    Parameters: Area under the plasma concentration versus time curve (AUC)

  5. Pharmacokinetics (PK) profile: CL/F [ Time Frame: First 5 weeks after initial administration of CX1003 ]
    Parameters: Apparent body clearence from plasma (CL/F)

  6. Pharmacokinetics (PK) profile: Vz/F [ Time Frame: First 5 weeks after initial administration of CX1003 ]
    Parameters: Apparent volume of distribution (Vz/F)

  7. Objective Response Rate (ORR) [ Time Frame: up to 24 months ]
    Overall response rate (ORR) was defined as the percentage of participants with a best overall complete response (CR) or partial response (PR) per RECIST 1.1.

  8. Progression-free survival (PFS) [ Time Frame: up to 24 months ]
    Progression-free survival (PFS) was defined as the time from the start date of study drug to the date of the first radiologically documented progressive disease (PD) per RECIST 1.1 or death due to any cause.

  9. Disease Control Rate (DCR) [ Time Frame: up to 24 months ]
    Disease Control Rate (DCR) was defined as the percentage of participants with a best overall complete response (CR), partial response (PR), or stable disease (SD) per RECIST 1.1.

  10. Duration of Response (DOR) [ Time Frame: up to 24 months ]
    Duration of response (DOR) was defined as the time from first documented response (partial response (PR) or complete response (CR)) to the date of first documented disease progression (PD) or death due to any cause, among patients with a confirmed PR or CR per RECIST 1.1.

  11. Safety profile as assessed by the incidence, duration, and severity of adverse events [ Time Frame: From first dose of CX1003 to 30 days after last dose ]
    Incidence, duration, and severity of AEs measured by laboratory assessments and physical findings according to NCI CTCAE 5.0.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed recurrent or metastatic solid tumors;
  • At least one measurable lesion (spiral CT scan long diameter ≥10 mm or enlarged lymph node short diameter ≥15 mm by RECIST 1.1);
  • Documented disease progression after, or refractory to, or intolerant of prior standard or established therapy known to provide clinical benefit for their condition; or documented disease progression within 24 weeks after prior adjuvant/neoadjuvant therapy;
  • ECOG PS ≤1;
  • Expected overall survival≥12 weeks;

Exclusion Criteria:

  • Untreated brain metastases or symptoms of brain metastases cannot be controlled more than 4 weeks;
  • Other kinds of malignancies [excluding stage IB or lower grade cervical cancer,noninvasive basal cell or squamous cell cancer, breast cancer with complete remission (CR) > 10 years ,melanoma with CR > 10 years or other malignant tumors with CR > 5 years];
  • Hematologic, renal, and hepatic function abnormities as defined below:

Absolute neutrophil count (ANC) <1.5×109 /L or platelet <100×109 /L or hemoglobin <9 g/dL; Total bilirubin > 1.5×the upper limit of normal range(ULN) without liver metastases; total bilirubin > 3×ULN with liver metastases; AST, ALT, ALP >1.5×ULN without liver metastases ; AST, ALT, ALP >5×ULN with liver metastases; Primary hepatocellular carcinoma; Hepatic cirrhosis with Child-Pugh B or C; Serum creatinine >1.5×ULN; History of previous nephrotic syndrome; INR or aPPT >1.5×ULN; Presence of hemorrhage (hemoptysis) , thrombosis,or currently receiving treatment with warfarin, aspirin, low molecular weight heparin (LMWH), or any other anti-platelet drugs (Aspirin ≤100 mg/d for prophylaxis are allowed); •Any of the following gastrointestinal disease: Unable to swallow oral drugs; Need intravenous nutrition; History of a gastric resection; History of treatment for active peptic ulcer disease within 6 months; Clinically significant gastrointestinal bleeding within 3 months; Persistent grade 2 or higher chronic diarrhea despite optimal medical management;

•Any of the following cardiovascular and cerebrovascular disease: Myocardial infarction , severe cardiac arrhythmias, unstable angina, coronary artery disease, congestive heart failure, cerebrovascular accident or TIA within 12 months ; Deep vein thrombosis or pulmonary embolism within 6 months; QTcF >470 msec; Uncontrolled hypertension despite optimal medical management;

  • Presence of unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5.0 grade 0 or 1 with the exception of alopecia;
  • Involved in other clinical trials within 30 days of enrollment;
  • Major surgical procedure, open biopsy, or significant traumatic injury within 30 days of enrollment;
  • History of organ allograft ;
  • Need glucocorticoids or other immunosuppressive agents for immunosuppression (excluding local or inhaled glucocorticoids);
  • Uncontrolled ongoing or active infection;
  • Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy;
  • Pregnant or lactating women or those who do not take contraceptives, including men;
  • Suffering from mental and neurological diseases;
  • Any other metabolic dysfunction, abnormal physical examination findings, or clinical laboratory findings;
  • Inability to comply with protocol required procedures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04093466


Contacts
Layout table for location contacts
Contact: Junyu Wu, Ph.D 0086-10-53056686 ext 2063 wujy@konruns.cn

Locations
Layout table for location information
China, Beijing
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Recruiting
Beijing, Beijing, China, 100021
Contact: Yuankai Shi, Dr    008610-87788507    syuankai@cicams.ac.cn   
Sponsors and Collaborators
Beijing Konruns Pharmaceutical Co., Ltd.
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
West China Hospital
Beijing Tongren Hospital
Investigators
Layout table for investigator information
Principal Investigator: Yuankai Shi, Doctor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Layout table for additonal information
Responsible Party: Beijing Konruns Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier: NCT04093466    
Other Study ID Numbers: KNTN-I-02
First Posted: September 18, 2019    Key Record Dates
Last Update Posted: January 14, 2022
Last Verified: December 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms